Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8 USD | -3.26% | -11.01% | -1.23% |
25/04 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
25/04 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.23% | 79.16M | |
+32.95% | 698B | |
+26.51% | 568B | |
-4.97% | 358B | |
+18.83% | 328B | |
+3.54% | 283B | |
+15.70% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+6.70% | 165B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- HC Wainwright Adjusts HOOKIPA Pharma Price Target to $6.50 From $8, Maintains Buy Rating